Methylprednisolone Should NOT Be Administered in Cervical Spine Trauma
Do not administer methylprednisolone to adults with acute traumatic cervical spinal cord injury. The 2020 French guidelines issue a GRADE 1 strong recommendation against early steroid administration, and the FDA label explicitly warns against its use in traumatic brain injury, with similar concerns extending to spinal cord injury 1, 2.
Guideline Consensus Against Methylprednisolone
The 2020 French spinal cord injury guidelines provide a GRADE 1 (strong) recommendation against administering steroids after traumatic spinal cord injury to improve neurological prognosis 1.
The 2013 Congress of Neurological Surgeons guidelines downgraded methylprednisolone from Class I to Class III evidence because all primary (a priori) outcome measures in the NASCIS trials were negative—any reported benefits came from post hoc analysis, which constitutes fishing expeditions rather than valid scientific evidence 1.
The FDA drug label explicitly states that high-dose systemic corticosteroids should NOT be used for traumatic brain injury due to increased mortality at 2 weeks and 6 months, and warns of serious neurologic adverse events including spinal cord infarction, paraplegia, and quadriplegia 2.
Evidence Shows No Neurological Benefit
NASCIS 1 compared two steroid doses (1g vs 100mg) and found no difference in neurological improvement between groups; there was no placebo control, making any conclusions about efficacy impossible 1.
NASCIS 2 reported only a modest motor score improvement at 6 months in patients treated within 8 hours, but this finding emerged from post hoc subgroup analysis without pre-specified endpoints, and lacked standardized long-term assessment 1.
NASCIS 3 compared 24-hour versus 48-hour steroid infusions and found no additional motor improvement with longer treatment, only increased complications 1.
A large Canadian propensity-score matched cohort study (1,555 controls, 46 treated) found no improvement in one-year motor function when controlling for neurological level and baseline severity—the two most important prognostic factors 1, 3.
A 2023 reanalysis of pooled NASCIS2 and Sygen data using contemporary statistical methods and modern inclusion criteria found no enhancement in ASIA motor score recovery at 26 weeks with methylprednisolone administration 4.
Significant Harm Profile
Infectious complications are consistently higher in steroid-treated patients: NASCIS 2 showed 7% infection rate versus 3% in placebo (trend toward significance), and the Canadian cohort demonstrated significantly higher total complication rates (61% vs 36%, p=0.02) 1, 3.
Pulmonary and urinary tract infections occur more frequently in patients receiving methylprednisolone across multiple studies 1.
The FDA label warns of cardiac arrhythmias and cardiac arrest following rapid administration of large IV doses (>0.5g in <10 minutes), as well as increased risk of left ventricular free wall rupture post-myocardial infarction 2.
Benzyl alcohol toxicity is a concern, particularly in neonates and small preterm infants, with reports of deaths associated with excessive exposure 2.
What SHOULD Be Done Instead
Maintain mean arterial pressure >70 mmHg for the first 5-7 days post-injury using continuous arterial line monitoring to optimize spinal cord perfusion pressure (target >50 mmHg correlates with better 6-month neurological status) 1.
Transfer immediately to a specialized spinal cord injury center (GRADE 2+ recommendation)—this intervention actually reduces morbidity and long-term mortality, unlike steroids 1.
Obtain early MRI when neurological deficits are unexplained by CT scan to identify medullary compression, contusion, ligament injury, herniated disc, or epidural hematoma that may require urgent surgical decompression 1.
Avoid hypotension rigorously (systolic BP <90 mmHg) throughout the acute phase, as secondary ischemic injury significantly worsens outcomes 1.
Critical Practice Change
Between 2008-2009,70% of patients at North American Clinical Trials Network centers received steroids; by 2010 this dropped to 20%, and by 2013-2018 only 4-17% received steroids following publication of updated guidelines 5.
In Switzerland, methylprednisolone use dropped from 96% (2001-2003) to 23% (2008-2010) after new guidelines, with no difference in neurological outcomes between the two time periods 6.
Common Pitfall to Avoid
Do not delay transfer to a specialized center or other proven interventions while considering methylprednisolone—the drug provides no neurological benefit and increases infection risk, whereas delayed specialized care is associated with worse outcomes 1, 7.
The evidence is clear and consistent: methylprednisolone should not be used in acute cervical spinal cord injury. Focus instead on hemodynamic optimization and rapid transfer to specialized care.